In Brief: Pillar Point Partners
This article was originally published in The Gray Sheet
Executive Summary
Pillar Point Partners: Files patent infringement suit Sept. 9 in the U.S. District Court for Arizona against Phoenix-based Barney Dulaney Eye Center. The suit charges Dulaney with "performing laser eye surgery without a license" from the Pillar Point partnership formed in 1992 to license Summit Technology's and Visx' excimer laser technology, according to a Sept. 10 Pillar Point press release. Pillar Point files a separate suit Sept. 9 in the U.S. District Court for the District of Columbia against Washington, D.C.-based consultant William Appler for allegedly "aiding and encouraging others, including eye clinics and medical personnel, to infringe the patented technology" of the partnership. Appler has represented ophthalmic surgeons that use custom-built and reimported excimer lasers for photorefractive keratectomy and laser in situ keratomileusis (LASIK), advising the physicians on FDA policy toward the unapproved lasers...
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.